Cotellic

DRUG2 trials

Sponsors

F. Hoffmann-La Roche AG

Conditions

Advanced MalignanciesPersistent or Recurrent Rare Epithelial Ovarian Tumors

Phase 2

A Phase II, Open-Label, Multicenter, Platform Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients with Persistent or Recurrent Rare Epithelial Ovarian Tumors

Active, not recruitingCTIS2023-508194-89-00

F. Hoffmann-La Roche AGPersistent or Recurrent Rare Epithelial Ovarian Tumors

Start: 2021-08-30Target: 57Updated: 2026-01-06

Phase 3

An open label, multicenter extension study in patients previously enrolled in a Genentch and/or F. Hoffmann-La Roche Ltd sponsored atezolizumab study (IMBRELLA B)

Active, not recruitingCTIS2023-506184-34-00

F. Hoffmann-La Roche AGAdvanced Malignancies

Start: 2019-08-09Target: 104Updated: 2025-11-10